The SURMOUNT program established tirzepatide as a chronic weight management therapy and produced the first FDA-approved drug for OSA. The trials cover obesity (SURMOUNT-1), OSA (SURMOUNT-OSA), and the cardiovascular endpoint (SURMOUNT-MMO, reading out 2026).

SURMOUNT-1 — the foundational trial

SURMOUNT-1 (Jastreboff et al., NEJM 2022) randomized 2,539 adults with obesity, without diabetes, to tirzepatide 5/10/15 mg weekly or placebo.

SURMOUNT-OSA — sleep apnea

Malhotra et al. (NEJM 2024) randomized adults with moderate-to-severe OSA + obesity to tirzepatide or placebo. Two parallel cohorts: on PAP therapy, and not on PAP therapy.

SURPASS-3 — head-to-head with insulin in T2D

Heise et al. (Lancet 2021) showed tirzepatide superior to titrated insulin degludec in T2D on A1c and weight endpoints, with lower hypoglycemia. Established tirzepatide as a guideline-aligned alternative to insulin initiation.

SURMOUNT-MMO — cardiovascular outcomes

Reads out 2026. If positive on MACE in obesity + CV risk, FDA cardiovascular indication for Zepbound expected to follow (mirroring the path SELECT created for Wegovy).

SYNERGY-NASH — tirzepatide in MASH

Loomba et al. (NEJM 2024) showed MASH resolution at 52 weeks: 44/56/62% by dose, vs 10% placebo. Phase 3 enrolling. See our MASH page.

Implications for current practice

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.